Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Epcoritamab, Zanubrutinib, and Rituximab (EZR) for Treatment of Relapsed or Refractory Follicular Lymphoma or Marginal Zone Lymphoma

NCT06563596 is registered in ClinicalTrials.gov with Reid Merryman, MD as lead sponsor.

NCT NCT06563596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06563596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Epcoritamab, Zanubrutinib, and Rituximab (EZR) for Treatment of Relapsed or Refractory Follicular Lymphoma or Marginal Zone Lymphoma
Lead sponsor
Reid Merryman, MD
Phase
Phase 2
Overall status
Recruiting
Start date
January 21, 2025
Completion date
March 1, 2032
Enrollment
71 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, lymphoma, marginal zone lymphoma, non-hodgkin lymphoma, refractory lymphoma, relapsed lymphoma